Search results
Showing 1 to 14 of 14 results for polycystic ovary syndrome
Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)
Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
Menopause: diagnosis and management Polycystic ovary syndrome: diagnosis and management Postnatal care -
In development Reference number: GID-NG10436 Expected publication date: 09 December 2026
NG198/2 Question Treatment options for people with polycystic ovary syndrome: What is the most effective first-line treatment option for...
treatment option for any severity of acne vulgaris for people with polycystic ovary syndrome? Any explanatory notes(if applicable) For a...
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
gonadotrophin-releasing hormone in women with clomifene citrate-resistant polycystic ovary syndrome is uncertain and is therefore not...
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.
View quality statements for QS143Show all sections
Sections for QS143
- Quality statements
- Quality statement 1: Diagnosing perimenopause and menopause
- Quality statement 2: Diagnosing premature ovarian insufficiency
- Quality statement 3: Managing premature ovarian insufficiency
- Quality statement 4: Reviewing treatments for menopause-associated symptoms
- Quality statement 5: Information before treatment likely to cause menopause
- Update information
- About this quality standard